BridgeBio Pharma company profile

BBIO · NASDAQ · USD

$78.30Change from previous close: +0.17%Absolute change: +$0.13

Close · November 13, 2026

Company profile

BridgeBio Pharma has 1,081 employees and is headquartered in Palo Alto, United States.

With 1,081 employees and revenue of 502.1 million USD in the fiscal year ended December 2025, BridgeBio Pharma discovers, develops and delivers medicines for patients with genetic diseases. Its offerings include Attruby, an oral treatment for cardiomyopathy linked to wild-type or transthyretin-mediated amyloidosis, and NULIBRY, an intravenous form of fosdenopterin for molybdenum cofactor deficiency. Late-stage candidates target achondroplasia and hypochondroplasia with low-dose infigratinib, hypocalcemia and hypoparathyroidism with encaleret, and LGMD2I with BBP-418, while the gene therapy BBP-812 addresses Canavan disease. Partners include Bayer Consumer Care, Alexion, Novartis and Leland Stanford Junior University.

The company recorded a net loss of 724.9 million USD in the same fiscal year. Founded in 2015, it is based in Palo Alto, California, and its programs also span mendelian and oncology conditions as well as gene therapy.

Company facts

Industry
Biotechnology
Headquarters
3160 Porter Drive, 94304, Palo Alto
Employees
1,081
Chief executive
Neil Kumar
Founded
2015
Fiscal year
January - December
Listing
BBIO · NASDAQ
Currency
USD
ISIN
US10806X1028

BridgeBio Pharma and its competitors

The most similar companies by business and size

CompanyCountryMarket capEmployeesOperating marginP/E (trailing 12 months)
BridgeBio PharmaBBIOUnited States$15.25B1,081-37.3%—
Jazz PharmaceuticalsJAZZUnited States$15.5B2,89027.4%71.5
ExelixisEXELUnited States$16.84B1,07740.2%20.7
Ascendis PharmaASNDUnited States$18.06B1,18930.9%18.1
Bio-TechneTECHUnited States$11.44B3,00021.7%66.8
Halozyme TherapeuticsHALOUnited States$11.43B42356.7%25.1

Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.

Compare BridgeBio Pharma with its competitors